Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celltrion To Jostle For Space In Crowded EU Bevacizumab Market

As Celltrion Also Submits Phase III Interchangeable Humira Data

Executive Summary

The European Commission has approved Vegzelma, a bevacizumab biosimilar developed by South Korean biopharma giant Celltrion. Vegzelma joins nine other bevacizumab biosimilar marketing authorization applications approved in the EU, promising to intensify price competition for the  critical late-stage cancer treatment.

You may also be interested in...



Celltrion’s Vegzelma Becomes Fourth US-Approved Bevacizumab

Celltrion’s Vegzelma earns a long-awaited USFDA approval. The oncology biosimilar will be up against established bevacizumab products from Amgen and Pfizer as well as recent newcomer Amneal.

What’s Next? Five Things To Look Out For In September

As the fourth quarter of the year nears, plenty is on the horizon for industry, with senior management shifts and a slate of high-value launches in the US and Europe.

Samsung Bioepis And Organon Get First High-Concentration Adalimumab Nod In US

Samsung Bioepis and Organon have broken new ground for Humira biosimilars in the US after receiving the first FDA approval for a higher-strength 100mg/ml adalimumab biosimilar.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB152108

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel